# Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

> **NCT00163527** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2054 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Roflumilast

## Key facts

- **NCT ID:** NCT00163527
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 2054 (—)
- **Last updated:** 2016-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00163527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00163527, "Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00163527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*